Summary:

Mitotech S.A, based in Luxembourg, is developing SkQ1, a powerful antioxidant that directly targets mitochondria. As a cardiolipin peroxidation inhibitor, SkQ1 protects mitochondria from the effects of oxidative stress. This approach is meant to slow or halt mitochondrial dysfunction, providing a possible therapy for macular degeneration and other age-related diseases.

The company is currently undergoing a phase 2b/3 study for SkQ1 as a treatment for dry eye disease.

Website: Mitotech